Lotazadromcel

洛它阿托赛

Report date: 2026/02/06 20:01:23

Base Information

Drug NameLotazadromcel
Drug Alias NameAllogeneic human adipose-derived mesenchymal stem cell therapy (Cellular Biomedicine Group)CBM-ALAM.1异体人源脂肪间充质祖细胞疗法（西比曼生物）AlloJoinCBM-ALAM.1
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveOsteoarthritis, KneeOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCellular Biomedicine Group LtdWuxi Sebiman Biotechnology Co LtdCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveOsteoarthritis, Knee
Inactive IndicationsOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A